publication venue for
- EVALUATING INTERVENTIONS TO ELIMINATE HEPATITIS C AMONG PEOPLE WHO INJECT DRUGS IN THE UNITED STATES 2021
- TAILORING VS UNIVERSAL PRECAUTIONS: HOW SHOULD WE SUPPORT SELF MANAGEMENT BEHAVIOURS AMONGST PATIENTS WITH DIVERSE HEALTH LITERACY NEEDS? 2021
- INCORPORATING MORTALITY IN HEALTH UTILITY MEASURES 2020
- UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW 2020
- Should Clinicians Deliver Decision Aids? Further Exploration of the Statin Choice Randomized Trial Results 2009
- A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored 2002
- A multilinear multi-attribute utility function for the health utilities index mark 3 (HUI3) 1998
- Economic evaluation of donepezil for treatment of Alzheimer's disease in Canada 1998
- The cost effectiveness of prenatal diagnosis: Does the 35-year-old threshold make sense? 1998
- A MARKOV COST-UTILITY MODEL ON THE PROVISION OF ERYTHROPOIETIN (EPO) FOR CHRONIC-HEMODIALYSIS (HD) PATIENTS 1991
- COMPARISON OF 2 HOSPITAL TUBERCULOSIS SURVEILLANCE PROGRAMS - RISKS AND BENEFITS 1983
- COST-EFFECTIVENESS ANALYSIS (CEA) COMPARING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD) TO HOSPITAL HEMODIALYSIS (HD) 1983
- COST-EFFECTIVENESS ANALYSIS OF A STRATEGY TO IMPROVE PATIENT COMPLIANCE WITH ANTIHYPERTENSIVE THERAPY 1983
- QUANTIFYING THE RELATIVE VALUE OF SPECIFIC HEALTH ATTRIBUTES TO OVERALL WELL-BEING - APPLICATION OF A FRACTIONAL FACTORIAL EXPERIMENTAL-DESIGN 1983
- THE ACCURACY OF PRIMARY CARE PHYSICIANS POST-TEST ESTIMATES OF DIAGNOSTIC LIKELIHOOD 1983
- Incorporating Social Determinants of Health in Infectious Disease Models: A Systematic Review of Guidelines.. 44:742-755. 2024
- Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly. 44:405-414. 2024
- Bayesian Models with Spatial Correlation Improve the Precision of EQ-5D-5L Value Sets. 43:587-594. 2023
- Noninferiority Margin Size and Acceptance of Trial Results: Contingent Valuation Survey of Clinician Preferences for Noninferior Mortality. 42:832-836. 2022
- A Systematic Literature Review of Health Utility Values in Breast Cancer. 42:704-719. 2022
- Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease. 41:685-692. 2021
- A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. 40:897-911. 2020
- Incorporating Mortality in Health Utility Measures. 40:862-872. 2020
- A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017. 40:582-595. 2020
- Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. 40:483-497. 2020
- Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. 39:421-436. 2019
- Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). 39:371-379. 2019
- Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. 38:968-982. 2018
- Future Directions for Cost-effectiveness Analyses in Health and Medicine. 38:767-777. 2018
- Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS®-Preference (PROPr) Scoring System. 38:683-698. 2018
- Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. 38:26-33. 2018
- Handling Regional Variation in Health State Preferences within a Country. 37:252-261. 2017
- Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments. 37:262-272. 2017
- Dissemination of Clinical Practice Guidelines. 36:692-702. 2016
- Expected Value of Sample Information with Imperfect Implementation. 36:282-283. 2016
- Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index. 36:264-274. 2016
- Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility. 36:223-233. 2016
- The CREATE Method for Expressing Continuous Outcome Data in Absolute Terms for Use in Patient Treatment Decision Aids. 35:959-966. 2015
- Underestimation of Uncertainties in Health Utilities Derived from Mapping Algorithms Involving Health-Related Quality-of-Life Measures. 34:863-872. 2014
- Sample Size and Power When Designing a Randomized Trial for the Estimation of Treatment, Selection, and Preference Effects. 34:711-719. 2014
- Comparing EQ-5D Valuation Studies. 34:8-20. 2014
- Scoring the 5-Level EQ-5D. 33:567-578. 2013
- Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions. 33:316-319. 2013
- The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis. 33:437-450. 2013
- Generalized Additive Models for the Analysis of EQ-5D Utility Data. 33:244-251. 2013
- Agreement about Identifying Patients Who Change over Time. 32:273-286. 2012
- Calculating Utility Decrements Associated With an Adverse Event. 31:790-799. 2011
- Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. 31:790-799. 2011
- Determining the Impact of Informed Choice. 31:229-236. 2011
- Standard Error of Measurement of 5 Health Utility Indexes across the Range of Health for Use in Estimating Reliability and Responsiveness. 31:260-269. 2011
- Presenting the Results of Cochrane Systematic Reviews to a Consumer Audience: A Qualitative Study. 30:566-577. 2010
- Capacity Constraints and Cost-Effectiveness: A Discrete Event Simulation for Drug-Eluting Stents. 30:16-28. 2010
- Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation. 28:471-480. 2008
- The Option Value of Delay in Health Technology Assessment. 28:300-305. 2008
- Health Technology Assessment in the Cost-Disutility Plane. 28:172-181. 2008
- A Second-Order Simulation Model of the Cost-Effectiveness of Managing Dyspepsia in the United States. 28:44-55. 2008
- Shared Decision Making in the Medical Encounter: Are We All Talking about the Same Thing?. 27:539-546. 2007
- Bedside Rationing by Health Practitioners: A Case Study in a Ugandan Hospital. 27:44-52. 2007
- Measuring Health Preferences for Health Utilities Index Mark 3 Health States: A Study of Feasibility and Preference Differences among Ethnic Groups in Singapore. 27:61-70. 2007
- As Good As It Gets but Good Enough for Which Applications?. 26:307-309. 2006
- Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. 25:548-559. 2005
- DEALE-ing with Lung Cancer and Heart Failure. 25:82-94. 2005
- Unfinished Symphony: A Tribute to the Life and Career of Bernie O’Brien (1959–2004). 24:538-544. 2004
- A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease. 24:53-60. 2004
- A Comparison of the Health Utilities Indices Mark 2 and Mark 3 in Type 2 Diabetes. 23:489-501. 2003
- Switching Therapy in Health Economics Trials: Confronting the Confusion. 23:335-340. 2003
- A Clinical Trial to Evaluate the Measurement Properties of 2 Direct Preference Instruments Administered with and without Hypothetical Marker States. 23:140-149. 2003
- Willingness to Pay for What? A Note on Alternative Definitions of Health Care Program Benefits for Contingent Valuation Studies. 22:493-497. 2002
- Primary Prevention Drug Therapy: Can It Meet Patients’ Requirements for Reduced Risk?. 22:326-339. 2002
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. 22:290-308. 2002
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. 22:290-308. 2002
- A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored. 22:173-177. 2002
- How robust is the Health Utilities Index Mark 2 utility function?. 22:350-358. 2002
- Looking back and looking forward: viewed through the eyes of George Torrance.. 22:178-181. 2002
- Book Review: Decision Making in Health Care: Theory, Psychology and Applications. 21:252-253. 2001
- Visual analog scales: do they have a role in the measurement of preferences for health states?. 21:329-334. 2001
- What should be reported in a methods section on utility assessment?. 21:200-207. 2001
- A Comparison of HU12 and HU13 Utility Scores in Alzheimer's Disease. 20:413-422. 2000
- The Cochrane Collaboration-Advances and Challenges in Improving Evidence-based Decision Making. 18:2-9. 1998
- Can Preference Scores for Discrete States Be Used to Derive Preference Scores for an Entire Path of Events?. 17:42-55. 1997
- HYEs: Do We Need Them and Can They Fulfil the Promise?. 16:215-216. 1996
- When Do the "Dollars" Make Sense?. 16:288-299. 1996
- Time in Health. 15:31-37. 1995
- Development of a Central Matching System for the Allocation of Cadaveric Kidneys. 14:124-136. 1994
- Healthy-years Equivalents versus Quality-adjusted Life Years. 13:287-292. 1993
- RISKS IN UTILITY-ASSESSMENT AND RISKS OF MEDICAL INTERVENTIONS - REPLY. 13:168-169. 1993
- The Healthy-years Equivalents. 11:140-146. 1991
- In reply. 10:149-149. 1990
- Nindsight: Artifacts and Treatment Effects. 9:217-218. 1989
- Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents. 9:142-149. 1989
- A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital Hemodialysis. 4:489-500. 1984